Mara Goldstein
Stock Analyst at Mizuho
(2.90)
# 1,779
Out of 5,049 analysts
74
Total ratings
44.83%
Success rate
9.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $10.16 | +195.28% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.31 | +332.90% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $7.93 | +0.88% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $19.56 | +114.72% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $14.00 | +257.14% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $14.69 | +206.33% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $105.24 | -26.83% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.24 | +212.50% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.04 | +669.23% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.41 | +2,839.74% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $55.12 | +63.28% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $7.80 | -55.13% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.66 | +21,586.75% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.62 | +202.11% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $85.78 | +51.55% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.19 | -52.27% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.36 | +782.35% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $60.30 | -66.83% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $8.37 | +473.48% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $23.26 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.65 | +147.79% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $10.16
Upside: +195.28%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.31
Upside: +332.90%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $7.93
Upside: +0.88%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $19.56
Upside: +114.72%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $14.00
Upside: +257.14%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $14.69
Upside: +206.33%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $105.24
Upside: -26.83%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.24
Upside: +212.50%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.04
Upside: +669.23%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.41
Upside: +2,839.74%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $55.12
Upside: +63.28%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $7.80
Upside: -55.13%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.66
Upside: +21,586.75%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.62
Upside: +202.11%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $85.78
Upside: +51.55%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.19
Upside: -52.27%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.36
Upside: +782.35%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $60.30
Upside: -66.83%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $8.37
Upside: +473.48%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $23.26
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.65
Upside: +147.79%